Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUNAR: Nadofaragene Firadenovec for Low-grade Upper Tract Urothelial Carcinoma
2024-514360-70-00Phase 2Authorised
- Sponsor
- Ferring Pharmaceuticals
- Start
- Sep 2025
- Modality
- Gene Therapies
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of nadofaragene firadenovec in upper tract urothelial carcinoma (UTUC), sponsored by Ferring Pharmaceuticals. Planned start Sep 2025; status: authorised.
02
Drugs
nadofaragene firadenovec
03
Conditions
upper tract urothelial carcinoma (UTUC)
Beyond the preview
Go deeper on 2024-514360-70-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514360-70-00.